Abstract
Human papillomavirus (HPV) is the cause of most cases of cervical cancer. HPV type 58 (HPV58) is the second most frequent cause of cervical cancer and high-grade squamous intraepithelial lesions (HSIL) in Asia and South / Central America, respectively. However, there is no vaccine against HPV58, although there are commercially available vaccines against HPV16 and 18. In this study, we produced HPV58 L1 protein from Saccharomyces cerevisiae, and investigated its immunogenicity. We first determined the optimum period of culture for obtaining HPV58 L1. We found that a considerable portion of the HPV58 L1 resulting from 48 h culture cannot be recovered by purification, while the HPV58 L1 resulting from 144 h culture is recovered efficiently: the yield of HPV58 L1 finally recovered from 144 h culture was 2.3 times higher than that from 48 h culture, although the production level of L1 protein from 144 h culture was lower than that from 48 h culture. These results indicate that the proportion of functional L1 protein from 144 h-cultured cells is significantly higher than that of 48 h-cultured cells. The HPV58 L1 purified from the 144 h culture was correctly assembled into structures similar to naturally occurring HPV virions. Immunization with the HPV58 L1 efficiently elicited anti-HPV58 neutralizing antibodies and antigen-specific CD4+ and CD8+ T cell proliferations, without the need for adjuvant. Our findings provide a convenient method for obtaining substantial amounts of highly immunogenic HPV58 L1 from S. cerevisiae.
Citations
Citations to this article as recorded by

- Expression, purification, and immunogenicity study of human papillomavirus type 52 virus-like particles produced in Hansenula polymorpha
Sheila Chairunnisa, Apon Zaenal Mustopa, Budiman Bela, Rosyida Khusniatul Arifah, Rifqiyah Nur Umami, Moh Egy Rahman Firdaus, Nurlaili Ekawati, Herman Irawan, Shasmita Irawan, Maritsa Nurfatwa, Ai Hertati, Sri Swasthikawati, Ela Novianti, Arizah Kusumawat
Biologicals.2025; 90: 101831. CrossRef - Yeast and Virus-like Particles: A Perfect or Imperfect Couple?
Sara Brachelente, Alvaro Galli, Tiziana Cervelli
Applied Microbiology.2023; 3(3): 805. CrossRef - Yeast-Based Virus-like Particles as an Emerging Platform for Vaccine Development and Delivery
Vartika Srivastava, Kripa N. Nand, Aijaz Ahmad, Ravinder Kumar
Vaccines.2023; 11(2): 479. CrossRef - How far have we explored fungi to fight cancer?
Chee Wun How, Yong Sze Ong, Sze Shin Low, Ashok Pandey, Pau Loke Show, Jhi Biau Foo
Seminars in Cancer Biology.2022; 86: 976. CrossRef - Yeast-based vaccines: New perspective in vaccine development and application
Ravinder Kumar, Piyush Kumar
FEMS Yeast Research.2019;[Epub] CrossRef - Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus
Maryam Dadar, Sandip Chakraborty, Kuldeep Dhama, Minakshi Prasad, Rekha Khandia, Sameer Hassan, Ashok Munjal, Ruchi Tiwari, Kumaragurubaran Karthik, Deepak Kumar, Hafiz M. N. Iqbal, Wanpen Chaicumpa
Frontiers in Immunology.2018;[Epub] CrossRef - The codon-optimized capsid gene of duck circovirus can be highly expressed in yeast and self-assemble into virus-like particles
Cui YANG, Yu XU, Ren-yong JIA, Si-yang LIU, Ming-shu WANG, De-kang ZHU, Shun CHEN, Ma-feng LIU, Xin-xin ZHAO, Kun-feng SUN, Bo JING, Zhong-qiong YIN, An-chun CHENG
Journal of Integrative Agriculture.2017; 16(7): 1601. CrossRef - A novel trivalent HPV 16/18/58 vaccine with anti-HPV 16 and 18 neutralizing antibody responses comparable to those induced by the Gardasil quadrivalent vaccine in rhesus macaque model
Fei Yin, Yajun Wang, Na Chen, Dunquan Jiang, Yefeng Qiu, Yan Wang, Mei Yan, Jianping Chen, Haijiang Zhang, Yongjiang Liu
Papillomavirus Research.2017; 3: 85. CrossRef - EV71 virus-like particles produced by co-expression of capsid proteins in yeast cells elicit humoral protective response against EV71 lethal challenge
Xiaowen Wang, Xiangqian Xiao, Miao Zhao, Wei Liu, Lin Pang, Xin Sun, Shan Cen, Burton B. Yang, Yuming Huang, Wang Sheng, Yi Zeng
BMC Research Notes.2016;[Epub] CrossRef - Therapeutic potential of an AcHERV-HPV L1 DNA vaccine
Hee-Jung Lee, Jong Kwang Yoon, Yoonki Heo, Hansam Cho, Yeondong Cho, Yongdae Gwon, Kang Chang Kim, Jiwon Choi, Jae Sung Lee, Yu-Kyoung Oh, Young Bong Kim
Journal of Microbiology.2015; 53(6): 415. CrossRef - Immunogenicity of a Trivalent Human Papillomavirus L1 DNA-Encapsidated, Non-Replicable Baculovirus Nanovaccine
Hansam Cho, Hee-Jung Lee, Yoon-Ki Heo, Yeondong Cho, Yong-Dae Gwon, Mi-Gyeong Kim, Ki Hoon Park, Yu-Kyoung Oh, Young Bong Kim, Shibo Jiang
PLoS ONE.2014; 9(4): e95961. CrossRef - The Concentration of Carbon Source in the Medium Affects the Quality of Virus-Like Particles of Human Papillomavirus Type 16 Produced in Saccharomyces cerevisiae
Hyoung Jin Kim, Yingji Jin, Hong-Jin Kim, Paulo Lee Ho
PLoS ONE.2014; 9(4): e94467. CrossRef - Panorámica de los receptores celulares del virus del papiloma humano y su repercusión en la purificación de partículas semejantes a virus
J.F. Beltrán-Lissabet
Vacunas.2014; 15(1-2): 29. CrossRef - Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice
Hao-Yang Li, Jian-Feng Han, Cheng-Feng Qin, Rong Chen
Vaccine.2013; 31(32): 3281. CrossRef